ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,156.42
0.56%
Dow Jones
38,783.76
0.28%
US Dollar vs MXN
16.9057
-0.46%
Brent Oil
83.495
0.45%
Bitcoin
63,849.34
-0.23%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) Noticias

OCGN Ocugen Inc

1.415
0.085 (6.39%)
Última actualización: 08:43:33
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ocugen Inc OCGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.085 6.39% 1.415 08:43:33
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.34 1.33 1.43 1.33
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202406:30GLOBEOcugen to Host Conference Call on Tuesday, May 14 at 8:30..
02/5/202406:15GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy at..
29/4/202405:45GLOBEOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data..
26/4/202408:05GLOBEUPDATE -- Ocugen to Present on Modifier Gene Therapy..
26/4/202405:30GLOBEOcugen to Present on Modifier Gene Therapy Platform at..
19/4/202406:13GLOBEOcugen Announces Dosing Completion of Subjects with..
12/4/202406:30GLOBEOcugen to Participate in Fireside Chat at the Emerging..
10/4/202406:02GLOBEOcugen, Inc. Announces Positive Scientific Advice from the..
08/4/202405:30GLOBEOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment..
05/4/202406:02GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
02/4/202407:00GLOBEOcugen Provides Business Update with Certain Financials for..
01/4/202417:08GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
01/4/202416:43GLOBEOcugen to Host Conference Call on Tuesday, April 2 at 8:30..
18/3/202405:30GLOBEOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical..
13/3/202407:00GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
06/3/202406:30GLOBEOcugen to Present at Investing in Cures Summit
28/2/202407:00GLOBEOcugen Clinical Showcase Webcast Now Available
26/2/202407:30GLOBEOcugen Chairman and CEO to present at Abu Dhabi Family..
22/2/202415:05GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
21/2/202415:05GLOBEOcugen to Present at 2024 BIO CEO & Investor Conference
21/2/202410:22EDGAR2Form 8-K - Current report
14/2/202406:30GLOBEOcugen to Host Clinical Showcase in New York City..
31/1/202407:00GLOBEOcugen to Present at Pharma Market Research Conference
16/1/202406:30GLOBEOcugen, Inc. Announces Bob Smith Joins Business Advisory..
08/1/202405:05EDGAR2Form 8-K - Current report
05/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202314:09EDGAR2Form 8-K - Current report
21/12/202305:30GLOBEOcugen Gains FDA Alignment on Key Aspects of OCU400—Modifier..
19/12/202306:30GLOBEOcugen Announces OCU400 Receives Regenerative Medicine..
13/12/202306:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
29/11/202306:30GLOBEOcugen CEO to Present at NobleCon19 – Noble Capital Markets’..
10/11/202306:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
09/11/202307:02EDGAR2Form 8-K - Current report
09/11/202306:02EDGAR2Form 8-K - Current report
09/11/202305:30GLOBEOcugen Provides Business Update with Third Quarter 2023..
09/11/202305:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:45GLOBEOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic..
02/11/202306:30GLOBEOcugen to Host Conference Call on Thursday, November 9 at..
10/10/202308:05EDGAR2Form 8-K - Current report
10/10/202305:30GLOBEOcugen Mucosal Vaccine Candidate OCU500 Selected by..
04/10/202306:00GLOBEOcugen to Present at the 2023 Cell & Gene Meeting on the..
29/9/202306:30GLOBEOcugen CSO to Participate in 4th Annual Gene Therapy for..
27/9/202318:30GLOBEOcugen to Participate in Fireside Chat at Chardan’s 7th..
21/9/202306:30GLOBEOcugen, Inc. Announces Connie Collingsworth Joins Business..
20/9/202307:00GLOBEOcugen to Participate in Panel at Cantor Fitzgerald Global..
19/9/202315:54EDGAR2Form 8-K - Current report
19/9/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
OCGN
Ocugen
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados